BACKGROUND AND PURPOSE: Current therapies for head and neck cancer frequently are not curative, necessitating novel therapeutic strategies. Thus, we studied whether inhibition of poly(ADP-Ribose) polymerase (PARP), a key DNA repair enzyme, could improve efficacy of radiotherapy in human head and neck cancer. MATERIALS AND METHODS: UM-SCC1, UM-SCC5, UM-SCC6, and FaDu human head and neck cancer cellular susceptibility to the PARP inhibitor (PARPi) ABT-888 and/or radiation (IR) was assessed using colony formation assays. DNA damage was evaluated using the alkaline comet assay and immunostaining for γ-H2AX foci. Non-homologous end-joining (NHEJ) mediated repair was measured using phospho-DNA-Pk foci. Epidermal growth factor receptor (EGFR) location was assessed by immunostaining. Poly ADP-Ribose polymerization (PAR) levels were assessed using immunoblotting. RESULTS: Human head and neck cancer cells exhibited enhanced cytotoxicity with IR and ABT-888 compared to either agent alone. This increased susceptibility correlated with reduced nuclear EGFR, attenuation of NHEJ, and persistence of DNA damage following IR. Interestingly, a subset of head and neck cancer cells which had elevated basal PAR levels was susceptible to PARPi alone. CONCLUSIONS: Combining radiotherapy and PARP inhibition may improve outcomes and quality of life for head and neck cancer patients treated with radiotherapy. Furthermore, this novel strategy may also be feasible in other tumor types. Moreover, PAR levels should be investigated as a potential biomarker for tumor susceptibility to PARP inhibition. Published by Elsevier Ireland Ltd.
BACKGROUND AND PURPOSE: Current therapies for head and neck cancer frequently are not curative, necessitating novel therapeutic strategies. Thus, we studied whether inhibition of poly(ADP-Ribose) polymerase (PARP), a key DNA repair enzyme, could improve efficacy of radiotherapy in humanhead and neck cancer. MATERIALS AND METHODS: UM-SCC1, UM-SCC5, UM-SCC6, and FaDu humanhead and neck cancer cellular susceptibility to the PARP inhibitor (PARPi) ABT-888 and/or radiation (IR) was assessed using colony formation assays. DNA damage was evaluated using the alkaline comet assay and immunostaining for γ-H2AX foci. Non-homologous end-joining (NHEJ) mediated repair was measured using phospho-DNA-Pk foci. Epidermal growth factor receptor (EGFR) location was assessed by immunostaining. Poly ADP-Ribose polymerization (PAR) levels were assessed using immunoblotting. RESULTS:Humanhead and neck cancer cells exhibited enhanced cytotoxicity with IR and ABT-888 compared to either agent alone. This increased susceptibility correlated with reduced nuclear EGFR, attenuation of NHEJ, and persistence of DNA damage following IR. Interestingly, a subset of head and neck cancer cells which had elevated basal PAR levels was susceptible to PARPi alone. CONCLUSIONS: Combining radiotherapy and PARP inhibition may improve outcomes and quality of life for head and neck cancerpatients treated with radiotherapy. Furthermore, this novel strategy may also be feasible in other tumor types. Moreover, PAR levels should be investigated as a potential biomarker for tumor susceptibility to PARP inhibition. Published by Elsevier Ireland Ltd.
Authors: Cherrie K Donawho; Yan Luo; Yanping Luo; Thomas D Penning; Joy L Bauch; Jennifer J Bouska; Velitchka D Bontcheva-Diaz; Bryan F Cox; Theodore L DeWeese; Larry E Dillehay; Debra C Ferguson; Nayereh S Ghoreishi-Haack; David R Grimm; Ran Guan; Edward K Han; Rhonda R Holley-Shanks; Boris Hristov; Kenneth B Idler; Ken Jarvis; Eric F Johnson; Lawrence R Kleinberg; Vered Klinghofer; Loren M Lasko; Xuesong Liu; Kennan C Marsh; Thomas P McGonigal; Jonathan A Meulbroek; Amanda M Olson; Joann P Palma; Luis E Rodriguez; Yan Shi; Jason A Stavropoulos; Alan C Tsurutani; Gui-Dong Zhu; Saul H Rosenberg; Vincent L Giranda; David J Frost Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: Sven Rottenberg; Janneke E Jaspers; Ariena Kersbergen; Eline van der Burg; Anders O H Nygren; Serge A L Zander; Patrick W B Derksen; Michiel de Bruin; John Zevenhoven; Alan Lau; Robert Boulter; Aaron Cranston; Mark J O'Connor; Niall M B Martin; Piet Borst; Jos Jonkers Journal: Proc Natl Acad Sci U S A Date: 2008-10-29 Impact factor: 11.205
Authors: Shivaani Kummar; Robert Kinders; Martin E Gutierrez; Larry Rubinstein; Ralph E Parchment; Lawrence R Phillips; Jiuping Ji; Anne Monks; Jennifer A Low; Alice Chen; Anthony J Murgo; Jerry Collins; Seth M Steinberg; Helen Eliopoulos; Vincent L Giranda; Gary Gordon; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James H Doroshow Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: William M Bonner; Christophe E Redon; Jennifer S Dickey; Asako J Nakamura; Olga A Sedelnikova; Stéphanie Solier; Yves Pommier Journal: Nat Rev Cancer Date: 2008-11-13 Impact factor: 60.716
Authors: Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth Journal: Nature Date: 2005-04-14 Impact factor: 69.504
Authors: Sumin Han; J Chad Brenner; Aaron Sabolch; Will Jackson; Corey Speers; Kari Wilder-Romans; Karen E Knudsen; Theodore S Lawrence; Arul M Chinnaiyan; Felix Y Feng Journal: Neoplasia Date: 2013-10 Impact factor: 5.715
Authors: Monjri M Shah; Zachary C Dobbin; Somaira Nowsheen; Monica Wielgos; Ashwini A Katre; Ronald D Alvarez; Panagiotis A Konstantinopoulos; Eddy S Yang; Charles N Landen Journal: Gynecol Oncol Date: 2014-05-15 Impact factor: 5.482
Authors: Zhuo Zhang; Rajani Rajbhandari; Monica E Wielgos; Tiffiny S Cooper; Ling Zeng; Andres Forero; Francisco J Esteva; C Kent Osborne; Rachel Schiff; Albert F LoBuglio; Susan E Nozell; Eddy S Yang Journal: Mol Cancer Ther Date: 2018-03-28 Impact factor: 6.261
Authors: Jack M Su; Patrick Thompson; Adekunle Adesina; Xiao-Nan Li; Lindsay Kilburn; Arzu Onar-Thomas; Mehmet Kocak; Brenda Chyla; Evelyn McKeegan; Katherine E Warren; Stewart Goldman; Ian F Pollack; Maryam Fouladi; Alice Chen; Vincent Giranda; James Boyett; Larry Kun; Susan M Blaney Journal: Neuro Oncol Date: 2014-06-07 Impact factor: 12.300
Authors: Kim A Reiss; Joseph M Herman; Deborah Armstrong; Marianna Zahurak; Anthony Fyles; Anthony Brade; Michael Milosevic; Laura A Dawson; Angela Scardina; Patricia Fischer; Amy Hacker-Prietz; Robert J Kinders; Lihua Wang; Alice Chen; Sarah Temkin; Naomi Horiba; Lee-Anne Stayner; Lillian L Siu; Nilofer S Azad Journal: Gynecol Oncol Date: 2017-01-18 Impact factor: 5.482